EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Role of a spray-type anti-adhesion barrier (AdSpray®) in post-operative outcomes following robot-assisted radical cystectomy for bladder cancer

Yuki Oda, Makito Miyake, Tatsuki Miyamoto, Takuto Shimizu, Mitsuru Tomizawa, Shunta Hori, Yosuke Morizawa, Daisuke Gotoh, Yasushi Nakai, Nobumichi Tanaka, Kiyohide Fujimoto

Bladder · 2026

DOI: 10.14440/bladder.0281 ↗
AbstractBibliografische Angaben

Abstract

Background: Despite advances in robot-assisted radical cystectomy (RARC) for bladder cancer and enhanced recovery protocols, post-operative gastrointestinal complications—particularly ileus and bowel obstruction—remain a significant clinical problem. Objective: We investigated whether intraoperative AdSpray® (TERUMO) during RARC is associated with fewer post-operative complications and improved recovery, with a focus on gastrointestinal events. Methods: We retrospectively reviewed consecutive patients who underwent RARC with urinary diversion at a single tertiary hospital between June 2019 and March 2025. The primary endpoint was any post-operative complication within 90 days. Prespecified gastrointestinal complications included paralytic ileus, intestinal obstruction, anastomotic leak, and anastomotic stricture. Additional outcomes were time to first liquid intake, time to resumption of a normal diet, and time to discharge. Intestinal obstruction was defined as a computed tomography-demonstrated transition point with compatible clinical findings, and paralytic ileus as radiographic ileus without obstruction. One-to-one propensity score matching (PSM) was used to balance baseline characteristics between the AdSpray and non-AdSpray groups. Post-matching logistic regression was used to estimate associations with binary outcomes, and time-to-event outcomes were analyzed using Kaplan–Meier methods. Results: Among 71 patients, 17 (24%) received AdSpray, and 54 (76%) did not; PSM yielded two comparable cohorts (n = 17 each). AdSpray use was significantly associated with a lower 90-day incidence of intestinal obstruction in the matched cohorts (odds ratio = 0.15, 95% confidence interval = 0.02–0.88, p = 0.032). Times to resumption of oral intake and discharge were similar between groups (before PSM, log-rank p = 0.64; after PSM, log-rank p = 0.42). Conclusion: These retrospective findings are hypothesis-generating and suggest that intraoperative AdSpray use during RARC may be associated with a reduced 90-day incidence of intestinal obstruction; however, they should not be interpreted as definitive evidence of a causal relationship.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →